Study programmes 2009-2010
Faculty of Medicine
Advanced Master in Industrial Pharmacy

Information

Professor Ph. HUBERT
Analytical Chemistry Laboratory
Build. B36 - CHU - 4000 Liege
Phone : 04/366.43.16 - Fax : 04/366.43.17
e-mail address : Ph.Hubert@ulg.ac.be

Presentation

The Advaced Master in Industrial Pharmacy is the path followed by those who want to acquire the status of qualified person (pharmacist responsible for the compliance of medicines produced by pharmaceutical industry - Royal Decree of June 6, 1960) through a university education . To obtain this official recognition by the Department of Public Health, the degree must be supplemented by practical experience of 6 months in one or more firm (s) drug (s) holder (s) authorized to manufacture industrial medicine as provided by the Royal Decree of August 14, 1989.
The Advanced Master in Industrial Pharmacy prepares the student to conventional manufacturing tasks and analysis of drugs. The program also includes courses in news fields such as biotechnology, regulatory affairs, quality assurance, economic aspects of drug, clinical tests.
An interuniversity program involving the ULB, UCL and ULg was created in 1997.

Particular requierements

* The complementary Masters in Industrial Pharmacy is available to pharmacists holding a Belgian qualification or an equivalent recognised by the French Speaking Community of Belgium. Admission is subject to the specific regulations of each university.
* The selection of candidates will be carried out in each university in consultation with the other two institutions.
* For holder of a diploma non EU, see the programme of the university certificate of additional training in Pharmaceutical Sciences
http://progcours.ulg.ac.be/cocoon/programmes/TUR_MYPHAR.html

Duration

* One year of study, with the possibility of spreading the programme over two years after a recommendation supplied by the Jury of the host university.

Collegiality

Coordinator : Jacques CROMMEN
For the ULg: Vincent BIERLAIRE, Bruno BOULANGER, Corinne CHARLIER, Jean-Pierre DELPORTE, Laurence DENIS, Brigitte EVRARD, Philippe HUBERT, Bernard PIROTTE, André SCHEEN, Monique TITS, Jean-Michel VANDERHOFSTADT.
For the ULB : Karim AMIGHI, J CARLEER, Jean-Paul DEHAYE, Michel DEVLEESCHOUWER, Jean-Antoine. DE MUYLDER, Alain DE WEVER, Pierre DUEZ, Ghanem GHANEM, A. HEPBURN, Jean-Michel KAUFFMAN, Jean NEVE, Michel TYTGAT.
For the UCL : Jean CUMPS, Estelle DAGNEAUX, Catherine DRUEZ, Michel FRANZ, Jean GILLARD, Didier LAMBERT, Xavier MARCELIS, Joëlle QUETIN-LECLERCQ, Jean SCOUVART, Roger VERBEEK.

A single year

Compulsory courses

PHIN2004-1	*Active substances*				**6**
	- *Substances issues de recherches pharmacochimiques, part a* - Bernard PIROTTE	10	-	-	
	- *Substances issues de recherches pharmacochimiques, part b* - J. NÈVE	5	-	-	
	- *Substances issues des biotechnologies* - J.-P. DEHAYE	15	-	-	
	- *Substances d'origine naturelle, part a* - J. QUETIN#LECLERCQ	5	-	-	
	- *Substances d'origine naturelle, part b* - P. DUEZ	5	-	-	
	- *Produits radiopharmaceutiques* - Ghanem GHANEM	10	-	-	
PHIN2008-1	*Clinical viewpoints*				**6**
	- *Métabolisme des médicaments et paramètres pharmacocinétiques* - R. VERBEEK	20	-	-	
	- *Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques)* - André SCHEEN	20	-	-	
	- *Information et pharmacovigilance* - Corinne CHARLIER	10	-	-	
PHIN2013-1	*Quality assurance and pharmaceutical management*				**8**
	- *Economic aspects of drug development* - Dominique MARTIN	10	-	-	
	- *Principles of pharmaceutical management* - J.-M. VANDERHOFSTADT	10	-	-	
	- *Quality assurance, Part a: basic concepts and quality assurance organisation* - J. SCOUVART	20	-	-	

	- *Quality assurance, Part b: Analytical technology of procedures and risk analysis* - X. MARCELIS	7,5	-	-	
	- *English as applied to the pharmaceutical industry* - E. DAGNEAUX, D. LAMBERT	20	-	-	
	- *Pharmaceutical marketing* - Vincent BIERLAIRE	7,5	-	-	
PHIN2022-1	*Industrial pharmaceutical technology*				**8**
	- *Microbiologie pharmaceutique industrielle* - Michel DEVLEESCHOUWER	15	-	-	
	- *Préformulation et sélection des formes galéniques* - Karim AMIGHI	15	-	-	
	- *Production industrielle des formes galéniques* - Brigitte EVRARD	15	-	-	
	- *Génie pharmaceutique* - J. GILLARD	15	-	-	
	- *Aspects industriels du développement technologique y compris le conditionnement* - Brigitte EVRARD	10	-	-	
PHIN2023-2	*Drug analysis*				**7**
	- *Pratique des méthodes d'analyse et de contrôle pharmaceutique et biopharmaceutique, part a* - J.-M. KAUFFMAN	10	-	-	
	- *Pratique des méthodes d'analyse et de contrôle pharmaceutique et biopharmaceutique, part b* - Jacques CROMMEN	10	-	-	
	- *Validation des méthodes d'analyse pharmaceutique et biopharmaceutique, qualification de l'appareillage et préparation des échantillons pharmaceutiques* - Philippe HUBERT	20	-	-	
	- *Méthodes statistiques appliquées à l'industrie pharmaceutique* - J. CUMPS	15	-	-	
	- *Planification expérimentale* - Bruno BOULANGER	10	-	-	
PHIN2029-1	*Regulation and the medical-social environment*				**7**
	- *Législation et procédures appliquées à l'industrie pharmaceutique, part a* - C. DRUEZ	10	5	-	
	- *Législation et procédures appliquées à l'industrie pharmaceutique, part b : patents and copyright* - Michel TYTGAT	5	-	-	
	- *Environnement économique et médico-social du médicament* - Alain DE WEVER	10	-	-	
	- *Dossier CTD (Common Technical Document)* - J.-A. DE MUYLDER	15	-	-	
	- *Réglementations des études précliniques et cliniques, part a : Pharmacotoxicological files* - J. CARLEER	7,5	-	-	
	- *Réglementations des études précliniques et cliniques, part b : European and Belgian legislations* - A. HEPBURN	7,5	-	-	
	- *Aspects réglementaires particuliers, part a : medicines and food supplements made from plants* - Monique TITS	5	-	-	
	- *Aspects réglementaires particuliers, part b : Galenic development* - Karim AMIGHI	5	-	-	
MTFE2000-1	*Final work* - COLLÉGIALITÉ	-	-	-	**18**

Visits and seminars will be organised in pharmaceutical industries.